Novartis Entresto gets expanded indication in chronic heart failure by FDA
Novartis has received approval from the US Food and Drug Administration (FDA) after expanded indication for Entresto to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.